<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890953</url>
  </required_header>
  <id_info>
    <org_study_id>2016-06-005</org_study_id>
    <nct_id>NCT02890953</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pneumostem® for IVH in Premature Infants (Phase 2a)</brief_title>
  <official_title>Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of IVH in Premature Infants (Phase 2a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of a single
      intraventricular administration of Pneumostem® for treatment of Intraventricular hemorrhage
      (IVH) in high-risk premature infants by comparing Pneumostem-treated group with a control
      group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or shunt operation</measure>
    <time_frame>until 40 weeks of corrected age</time_frame>
    <description>Death or shunt operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ventricular dilatation</measure>
    <time_frame>until 40 weeks of corrected age</time_frame>
    <description>volume ratio of ventricle to whole brain in the brain MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>until 40 weeks of corrected age</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group receives placebo medication (normal saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSC group receives mesenchymal stem cells transplantation (Pneumostem)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pneumostem</intervention_name>
    <description>direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap</description>
    <arm_group_label>MSC group</arm_group_label>
    <other_name>Umbilical cord blood derived mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>direct intracerebroventricular injection of normal saline via ventricular tap</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IVH grade 3-4

          -  age : within postnatal day 28

          -  gestational age: 23-&lt;34 weeks

        Exclusion Criteria:

          -  Patient with severe congenital abnormalities

          -  Patient with antenatal brain hemorrhage

          -  Patient with asphyxia or Hypoxic ischemic encepalophathy

          -  Patient with chromosome anomalies (i.e. Edward syndrome, Patau syndrome, Down
             syndrome, etc) or severe congenital malformation (Hydrocephalus, Encephalocele, etc)

          -  Patient with a concurrent severe congenital infection (i.e. Herpes, Toxoplasmosis,
             Rubella, Syphilis, AIDS, etc)

          -  Patient withCRP &gt; 30 mg/dL; Severe sepsis or shock

          -  Patient with severe intracranial hemorrhage ≥ grade 3 or 4

          -  Patient with a history of participating in other clinical studies

          -  Patient who is considered inappropriate to participate in the study by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>So Yoon Ahn, MD. Ph.D</last_name>
    <phone>+821040380460</phone>
    <email>soyoon.ahn@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Won Soon Park, MD. Ph.D</last_name>
    <phone>+821099333523</phone>
    <email>ws123.park@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Yoon Ahn, MD</last_name>
      <phone>+82-02-3410-3745</phone>
      <email>yoon.ahn.neo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Won-Soon Park, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Soon Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

